These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 18973850

  • 1. Non invasive diagnosis of portal hypertension in cirrhotic patients.
    Vizzutti F, Arena U, Rega L, Pinzani M.
    Gastroenterol Clin Biol; 2008 Sep; 32(6 Suppl 1):80-7. PubMed ID: 18973850
    [Abstract] [Full Text] [Related]

  • 2. Non invasive evaluation of portal hypertension using transient elastography.
    Castera L, Pinzani M, Bosch J.
    J Hepatol; 2012 Mar; 56(3):696-703. PubMed ID: 21767510
    [Abstract] [Full Text] [Related]

  • 3. Liver elastography for the diagnosis of portal hypertension in patients with liver cirrhosis.
    Şirli R, Sporea I, Bota S, Raţiu I.
    Med Ultrason; 2012 Sep; 14(3):225-30. PubMed ID: 22957328
    [Abstract] [Full Text] [Related]

  • 4. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis.
    Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J, Portal Hypertension Collaborative Group.
    Gastroenterology; 2007 Aug; 133(2):481-8. PubMed ID: 17681169
    [Abstract] [Full Text] [Related]

  • 5. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement?
    Lim JK, Groszmann RJ.
    Hepatology; 2007 May; 45(5):1087-90. PubMed ID: 17464984
    [No Abstract] [Full Text] [Related]

  • 6. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis.
    Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, Grando-Lemaire V, Trinchet JC, Beaugrand M.
    Aliment Pharmacol Ther; 2008 Nov 01; 28(9):1102-10. PubMed ID: 18691352
    [Abstract] [Full Text] [Related]

  • 7. Non-invasive model predicting clinically-significant portal hypertension in patients with advanced fibrosis.
    Park SH, Park TE, Kim YM, Kim SJ, Baik GH, Kim JB, Kim DJ.
    J Gastroenterol Hepatol; 2009 Jul 01; 24(7):1289-93. PubMed ID: 19682196
    [Abstract] [Full Text] [Related]

  • 8. Non-invasive evaluation of liver fibrosis using transient elastography.
    Castera L, Forns X, Alberti A.
    J Hepatol; 2008 May 01; 48(5):835-47. PubMed ID: 18334275
    [Abstract] [Full Text] [Related]

  • 9. Invasive and non-invasive techniques for detecting portal hypertension and predicting variceal bleeding in cirrhosis: a review.
    Zardi EM, Di Matteo FM, Pacella CM, Sanyal AJ.
    Ann Med; 2014 Feb 01; 46(1):8-17. PubMed ID: 24328372
    [Abstract] [Full Text] [Related]

  • 10. Hepatic venous pressure gradient and outcomes in cirrhosis.
    Ripoll C.
    J Clin Gastroenterol; 2007 Feb 01; 41 Suppl 3():S330-5. PubMed ID: 17975485
    [Abstract] [Full Text] [Related]

  • 11. Liver cirrhosis.
    Pinzani M, Rosselli M, Zuckermann M.
    Best Pract Res Clin Gastroenterol; 2011 Apr 01; 25(2):281-90. PubMed ID: 21497745
    [Abstract] [Full Text] [Related]

  • 12. Serum laminin P1 levels do not reflect critically elevated portal pressure in patients with liver cirrhosis.
    Bahr MJ, Böker KH, Horn W, Günzler V, Manns MP.
    Hepatogastroenterology; 1997 Apr 01; 44(16):1200-5. PubMed ID: 9261625
    [Abstract] [Full Text] [Related]

  • 13. [Clinical approach to portal hypertension].
    González Galilea A, Fraga Rivas E, Miño Fugarolas G.
    An Med Interna; 2000 Sep 01; 17(9):496-503. PubMed ID: 11100539
    [Abstract] [Full Text] [Related]

  • 14. Steatosis and portal hypertension.
    Puoti C, Bellis L.
    Eur Rev Med Pharmacol Sci; 2005 Sep 01; 9(5):285-90. PubMed ID: 16231591
    [Abstract] [Full Text] [Related]

  • 15. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation.
    Carrión JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X.
    Liver Transpl; 2006 Dec 01; 12(12):1791-8. PubMed ID: 16823833
    [Abstract] [Full Text] [Related]

  • 16. [Measurement of hepatic venous pressure gradient in liver cirrhosis: relationship with the status of cirrhosis, varices, and ascites in Korea].
    Kim MY, Baik SK, Suk KT, Yea CJ, Lee IY, Kim JW, Cha SH, Kim YJ, Um SH, Han KH.
    Korean J Hepatol; 2008 Jun 01; 14(2):150-8. PubMed ID: 18617762
    [Abstract] [Full Text] [Related]

  • 17. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography.
    Rockey DC.
    Gastroenterology; 2008 Jan 01; 134(1):8-14. PubMed ID: 18166342
    [Abstract] [Full Text] [Related]

  • 18. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study.
    Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J.
    Am J Gastroenterol; 2010 May 01; 105(5):1094-101. PubMed ID: 19920806
    [Abstract] [Full Text] [Related]

  • 19. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis.
    Schneider AW, Kalk JF, Klein CP.
    Hepatology; 1999 Feb 01; 29(2):334-9. PubMed ID: 9918907
    [Abstract] [Full Text] [Related]

  • 20. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.
    Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A.
    Am J Gastroenterol; 2007 Jul 01; 102(7):1397-405. PubMed ID: 17488248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.